Immunogenicity and reactogenicity of an inactivated quadrivalent influenza vaccine administered intramuscularly to children 6 to 35 months of age in 2012-2013: A randomized, double-blind, controlled, multicenter, multicountry, clinical trial

Journal of the Pediatric Infectious Diseases Society

Volumn 4, Issue 3, 2015, Pages 242-251

  Langley, Joanne M ^a   Wang, Long ^b   Aggarwal, Naresh ^c   Bueso, Agustin ^d   Chandrasekaran, Vijayalakshmi ^b   Cousin, Luis ^d   Halperin, Scott A ^a   Li, Ping ^b   Liu, Aixue ^b   McNeil, Shelly ^a   Mendez, Lourdes Peña ^e   Rivera, Luis ^e   Innis, Bruce L ^b   Jain, Varsha K ^b  

^a DALHOUSIE UNIVERSITY   (Canada)

^b GLAXOSMITHKLINE   (United States)

^c Aggarwal and Associates Limited   (Canada)

^d Tecnologia en Investigacion   (Honduras)

^e Hospital Maternidad Ntra Sra de la Altagracia Gazcue   (Dominica)

Author keywords

Children; Immunogenicity; Influenza vaccine

Indexed keywords

INFLUENZA VACCINE; INACTIVATED VACCINE;

ARTICLE; CHILD; CONTROLLED STUDY; CROSS REACTION; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG SAFETY; FEMALE; FEVER; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFANT; INFLUENZA B VIRUS; INJECTION SITE PAIN; LOSS OF APPETITE; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SEROCONVERSION; SINGLE DRUG DOSE; VACCINATION; CANADA; CLINICAL TRIAL; COMPARATIVE STUDY; DOMINICAN REPUBLIC; HONDURAS; IMMUNOLOGY; INFLUENZA, HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; PHASE 3 CLINICAL TRIAL; PRESCHOOL CHILD; VACCINE IMMUNOGENICITY;

CANADA; CHILD, PRESCHOOL; DOMINICAN REPUBLIC; DOUBLE-BLIND METHOD; FEMALE; HONDURAS; HUMANS; IMMUNOGENICITY, VACCINE; INFANT; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; INJECTIONS, INTRAMUSCULAR; MALE; VACCINES, INACTIVATED;

EID: 85006184015     PISSN: 20487193     EISSN: 20487207     Source Type: Journal    
DOI: 10.1093/jpids/piu098     Document Type: Article

References (20)

1. Grohskopf LA, Shay DK, Shimabukuro TT, et al. Prevention and control of seasonal influenza with vaccines. MMWR Recomm Rep 2013; 62:1-43.
2. World Health Organization. Influenza vaccines and reagents. Available at: http://www.who.int/influenza/vaccines/virus/en/. Accessed 11 October 2013.
3. Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and metaanalysis. Lancet Infect Dis 2012; 12:36-44.
4. Committee on Infectious Diseases. Recommendations for prevention and control of influenza in children, 2013-2014. Pediatrics 2013; 132:e1089-104.
5. Reed C, Meltzer MI, Finelli L, Fiore A. Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine. Vaccine 2012; 30:1993-8.
6. Langley JM, Carmona Martinez A, Chatterjee A, et al. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate: a phase III randomized controlled trial in children. J Infect Dis 2013; 208:544-53.
7. Domachowske JB, Pankow-Culot H, Bautista M, et al. A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3-17 years. J Infect Dis 2013; 207:1878-87.
8. Greenberg DP, Robertson CA, Landolfi VA, et al. Safety and immunogenicity of an inactivated quadrivalent influenza vaccine in children 6 months through 8 years of age. Pediatr Infect Dis J 2014; 33:630-6.
9. Jain VK, Rivera L, Zaman K, et al. Vaccine for prevention of mild and moderate-to-severe influenza in children. N Engl J Med 2013; 369:2481-91.
10. Centers for Disease Control and Prevention. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP)-United States, 2012-13 influenza season. MMWR Morb Mortal Wkly Rep 2012; 61:613-8.
11. Hehme N, Künzel W, Petschke F, et al. Ten years of experience with the trivalent split-influenza vaccine, Fluarix. Clin Drug Investig 2002; 22:751-69.
12. US Department of Health and Human Services, Food and Drug Administration. Guidance for industry: clinical data needed to support the licensure of seasonal inactivated influenza vaccines. Available at: http://www.fda.gov/downloads/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/quidances/vaccines/ucm091990.pdf. Accessed 1 March 2013.
13. Skowronski DM, Hottes TS, Chong M, et al. Randomized controlled trial of dose response to influenza vaccine in children aged 6 to 23 months. Pediatrics 2011; 128:e276-89.
14. Langley JM, Vanderkooi OG, Garfield HA, et al. Immunogenicity and safety of 2 dose levels of a thimerosal-free trivalent seasonal influenza vaccine in children aged 6-35 months: a randomized, controlled trial. J Pediatr Infect Dis Soc 2012; 1:55-63.
15. Pavia-Ruz N, Angel Rodriguez Weber M, Lau YL, et al. A randomized controlled study to evaluate the immunogenicity of a trivalent inactivated seasonal influenza vaccine at two dosages in children 6 to 35 months of age. Hum Vaccin Immunother 2013; 9:1978-88.
16. Vesikari T, Knuf M, Wutzler P, et al. Oil-in-water emulsion adjuvant with influenza vaccine in young children. N Engl J Med 2011; 365:1406-16.
17. Della Cioppa G, Vesikari T, Sokal E, Lindert K, Nicolay U. Trivalent and quadrivalent MF59-adjuvanted influenza vaccine in young children: a dose-and schedule-finding study. Vaccine 2011; 29:8696-704.
18. Esposito S, Marchisio P, Ansaldi F, et al. A randomized clinical trial assessing immunogenicity and safety of a double dose of virosomal-adjuvanted influenza vaccine administered to unprimed children aged 6-35 months. Vaccine 2010; 28:6137-44.
19. Zangwill KM, Belshe RB. Safety and efficacy of trivalent inactivated influenza vaccine in young children: a summary for the new era of routine vaccination. Pediatr Infect Dis J 2004; 23:189-97.
20. Ruben FL. Inactivated influenza virus vaccines in children. Clin Infect Dis 2004; 38:678-88.